NCT07066267
Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)
StatusActive, Not Recruiting
PhaseNot applicable
SponsorSunkaky Medical Cooperation
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 16 words
- Enrollment closed, study ongoing
- Site details revised
- Publications: details revised at 3 of 3 entries
- Minor Publications: details revised at 3 of 3 entriesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Embryo development rate
Timeframe: Up to 8 weeks post-intervention
Secondary (6)
Ongoing clinical pregnancy rate after the first transfer
Chemical pregnancy rate
Live Birth rates
Pregnancy complication
Abortion rate
Show 1 moreShow less
Additional in vitro fertilization - outcome indicators
Arms and interventions
Autologous Mitochondria transferActive comparator
Mitochondria isolated from autologous adipose-derived stem cells are transplanted into the oocyte in conjunction with intracytoplasmic sperm injection (ICSI); Mito-ICSI group
Conventonal Intracytoplasmic Sperm InjectionNo intervention
Conventional ICSI; Control group
Other: Experimental
Sites
1 site in 1 country
- Wish Fertility Hospital Pvt. LtdColombo, Sri Lanka